ARQ-151 cream 0.05%

DRUG2 trials

Sponsors

Arcutis Biotherapeutics, Inc.

Conditions

Atopic Dermatitis (Eczema)

Phase 1

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

CompletedNCT04156191

Arcutis Biotherapeutics, Inc.Atopic Dermatitis (Eczema)

Start: 2019-12-23End: 2023-05-02Updated: 2023-07-24

Phase 2

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

CompletedNCT06998056

Arcutis Biotherapeutics, Inc.Atopic Dermatitis (Eczema)

Start: 2025-06-09End: 2025-12-04Updated: 2025-12-10